Efficacy and Safety of DEC103 in Pain Control Associated to Intrauterine Device (IUD) Insertion

Pain Clinical Trial

— DEC103  

Official title:

A National, Single Center, Randomized, Prospective, Phase IV, Double-blind, Placebo-controlled, Parallel Study to Assess the Efficacy and Safety of DEC103 in the Pain Control Associated With Intrauterine Device (IUD) Insertion

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05800392
• Other study ID #: DEC103-IV-0123
• Status: Completed
• Phase: Phase 4
• Start date: September 3, 2023
• Est. completion date: December 1, 2023

Study information

• Verified date: February 2024
• Source: EMS
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of DEC103 in the pain control associated with IUD insertion in women with 18 to 49 years.

Description:

The DEC103 treatment is composed by two different medications that are already available in brazilian market. One is a sublingual pill and the other is an oral one. The participants must take 02 (two) pills of the sublingual formulation and 01 (one) of the oral formulation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: December 1, 2023
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

• Patient has given written informed consent to participate in the study prior to admission;

• Female patients aged between 18 and 49 years old;

• First IUD users;

• Nulliparous women.

Exclusion Criteria:

• Any finding or clinical observation (clinical/physical evaluation) or laboratory condition that is interpreted by the investigating physician as a risk to the participation of the research participant in the clinical trial or presence of uncontrolled chronic disease(s);

• Presence of chronic pelvic pain and any uterine malformation;

• Presence of psychiatric disorder;

• Chronic use of medications that interfere with the pain threshold, for example:

antidepressants and anticonvulsants;

• Use of analgesics and/or ant-inflammatory in the last 24 hours prior the procedure;

• Any sign or symptom of vaginal or cervical infection;

• Participants with any contraindication to one or both medicines that constitute the DEC103 treatment;

• Actual abuse of alcohol or drugs;

• Participants who are nursing;

• Presence of known allergy or hypersensitivity to the components of the drugs used during the clinical trial;

• Participants with a current medical history of cancer and/or cancer treatment in the last five (05) years;

• Participation in a clinical research protocol in the last 12 months (CNS Resolution 251, of August 7, 1997, item III, subitem J), unless the investigator judges that there may be a direct benefit to it.

Related Conditions & MeSH terms

• Pain

Intervention

Drug:
• DEC103
The intervention is composed by two medications: An active sublingual pill and an active oral one.
• Placebo DEC103
The intervention is composed by two medications: A placebo sublingual pill and an placebo oral one.

Locations

Country	Name	City	State
Brazil	CEMICAMP - Centro de Pesquisas em Saúde Reprodutiva de Campinas	Campinas	SP

Sponsors (1)

Lead Sponsor	Collaborator
EMS

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of DEC103 in pain management associated to IUD insertion assessed by NRS.	Mean pain during the IUD insertion procedure during IUD deployment. The pain will be assessed through a Numeric Rating Scale (NRS), numbered from 0 (no pain) to 10 (worst pain possible).	During the procedure.
Primary	Efficacy of DEC103 in pain management associated to IUD insertion assessed by NRS.	Mean overall pain rating during the IUD insertion procedure. The pain will be assessed through a Numeric Rating Scale (NRS), numbered from 0 (no pain) to 10 (worst pain possible).	During the procedure.
Primary	Efficacy of DEC103 in pain management associated to IUD insertion assessed by NRS.	Mean pain 10 minuts after the IUD insertion The pain will be assessed through a Numeric Rating Scale (NRS), numbered from 0 (no pain) to 10 (worst pain possible).	10 minutes after de procedure.
Secondary	Efficacy of DEC103 in pain associated to IUD insertion assessed by NRS.	Mean pain during tenaculum placement and uterine sounding. The pain will be assessed through a Numeric Rating Scale (NRS), numbered from 0 (no pain) to 10 (worst pain possible).	During the procedure.
Secondary	Women's overall pain perception during the procedure assessed by a 4-point scale.	The global pain perception during the procedure will be assessed through a 4-point scale as the following: 0 = no pain; 1 = mild pain; 2 = moderate pain; 3 = intense pain	During the procedure.
Secondary	Physician's perception regarding ease of IUD insertion assessed by the following options: easy, moderate and difficult.	Physician's perception will be assessed through a questionnaire with the following options: easy, moderate and difficult.	Immediately after the procedure.